This resolution expresses support for the six protected classes of prescription drugs under the Medicare prescription drug benefit: antidepressants, antipsychotics, anticonvulsants, immunosuppressants, antiretrovirals, and antineoplastics.
[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1390 Introduced in House (IH)]
<DOC>
117th CONGRESS
2d Session
H. RES. 1390
Expressing support for the protection of Medicare part D's six
protected classes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 22, 2022
Mrs. Napolitano (for herself, Mr. Katko, Ms. Lee of California, Miss
Gonzalez-Colon, Mr. Fitzpatrick, Ms. Roybal-Allard, Ms. Matsui, Mr.
Soto, Mr. Trone, Mr. Sires, Mr. Grijalva, and Mr. Cardenas) submitted
the following resolution; which was referred to the Committee on Energy
and Commerce, and in addition to the Committee on Ways and Means, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
RESOLUTION
Expressing support for the protection of Medicare part D's six
protected classes.
Whereas Medicare part D was established by Congress in 2003 to provide much-
needed prescription drug coverage for seniors and people with
disabilities;
Whereas during implementation, the Centers for Medicare & Medicaid Services
(CMS) identified six classes and categories of medicines where patients
could face serious risks, complications, and negative health outcomes
without access to these medicines;
Whereas CMS requires part D plans to cover all or substantially all medication
within these six classes, which help protect patients needing
antidepressants, antipsychotics, anticonvulsants, immunosuppressants,
antiretrovirals, and antineoplastics;
Whereas these medications help treat patients with, but not limited to,
epilepsy, organ transplants, cancer, HIV/AIDS, and mental health
conditions;
Whereas, in the past, CMS has considered changes that impact the accessibility
of these medicines;
Whereas prior proposed changes would have permitted certain health plans to
limit or reduce coverage of drugs in the protected classes;
Whereas prior proposed changes have failed to consider the need for Medicare
beneficiaries to have access to treatments that are best for their
condition(s) or the necessity and challenges to determine the best
regimen to meet those needs;
Whereas if patients are unable to obtain the medicines they need, many will
experience costly and avoidable complications that could increase
overall costs to the Medicare Program, reduce their quality of life, or
even limit life itself;
Whereas such changes would directly target some of our most vulnerable citizens;
Whereas prior proposed changes are particularly worrisome given the unique,
often complex, medical needs of some Medicare beneficiaries;
Whereas beneficiaries with schizophrenia who are stabilized on medication and
then forced to utilize a different medicine are at risk of a relapse;
Whereas this would lead to higher medical costs in the form of potentially
avoidable psychiatric hospitalizations, as well as exacerbate patients'
comorbid medical conditions;
Whereas individuals with depression often need to try several medicines before
finding one that provides symptom relief;
Whereas having only one or two drugs to treat the wide-ranging ways someone
could present with depression is simply inadequate, especially among an
older population where depression is a significant predictor of suicide;
Whereas access to medications is essential for those who experience mental
health conditions, which are often co-occurring with other conditions,
such as Parkinson's disease;
Whereas for people living with HIV, new drug therapies have saved millions of
lives and prolonged millions more;
Whereas the advent of antiretroviral medications shifted the prognosis for an
individual diagnosed with HIV from a near-certain death to a manageable
disease, when patients have access to quality care and medications;
Whereas not all HIV/AIDS medications are the same, and each person may react
differently to a particular medication;
Whereas disruptions or delays in access to HIV treatment can have serious
consequences for patients and can increase the risk of HIV transmission
to others;
Whereas for people living with HIV, drug resistance can occur, and they must
have the ability to switch to another drug without interruption;
Whereas HIV disproportionately affects minority populations, and, in 2020, 43
percent of people newly diagnosed with HIV were Black, although Black
Americans represent only 12 percent of the United States population, and
in 2019, Hispanic people represented 29 percent of those newly diagnosed
with HIV but only 16 percent of the United States population;
Whereas access to oncology drugs (antineoplastics) is crucial for cancer
patients because drugs in these classes are not always interchangeable;
Whereas oncology patients may respond differently to different treatments, need
to access alternative treatments based on changes in their condition, or
have fewer or more tolerable side effects if they use one therapy
instead of another;
Whereas at least 1,100,000 Medicare beneficiaries live with epilepsy;
Whereas epilepsy medications, known as anticonvulsants or antiseizure
medications, are not interchangeable;
Whereas people with epilepsy who cannot access or are forced to switch from the
most effective anticonvulsant are at increased risk of breakthrough
seizures and related complications including injury, disability, and
death;
Whereas seizure-free individuals who are forced to switch their medication have
nearly a 17-percent rate of seizure reoccurrence compared to less than 3
percent among people remaining on the most effective medication;
Whereas eliminating immunosuppressants from the list of protected classes would
place persons who received any transplant at risk for severe medical
complications;
Whereas immunosuppressive medications are not interchangeable;
Whereas if prescription drugs are filled without regard to consistency from one
month to the next, the recipient is subject to increased risk of organ
rejection, along with additional clinic visits, lab costs, and potential
hospitalization;
Whereas this includes individuals who take these same medications to manage
their autoimmune disorders, including lupus, psoriasis, rheumatoid
arthritis, Crohn's disease, and multiple sclerosis;
Whereas part D plans are already equipped with tools to manage spending and
encourage the use of generics, when possible and appropriate, for the
six protected classes;
Whereas, according to an analysis of CMS data by the Pew Charitable Trusts, the
generic utilization rate in the six protected classes is as high as 92
percent; and
Whereas potential changes to the six protected classes have now been rejected
during the Obama, Trump, and Biden administrations after receiving
significant opposition from Congress, patient groups, providers, and
stakeholders: Now, therefore, be it
Resolved, That the House of Representatives--
(1) supports the six protected classes policy because it
established critical access protection for many of our most
vulnerable Medicare beneficiaries;
(2) recognizes that Medicare part D beneficiaries currently
needing antidepressants, antipsychotics, anticonvulsants,
immunosuppressants, antiretrovirals, and antineoplastics depend
on the protection of the six protected classes to meet their
complex medical needs and highly personalized treatments; and
(3) encourages the Centers for Medicare & Medicaid Services
to continue to work with Congress, patient groups, providers,
and stakeholders to secure long-term protection of the six
protected classes policy.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line